U.S., Dec. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07306598) titled '[18F]NIDF PET Imaging in Tau-related Diseases' on Dec. 14.
Brief Summary: In the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body. These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own tau imaging agents.
This clinical research project aims to visualize abnormal tau pathology in the living human brain using [18F]NIDF PET imaging. [18F]NIDF is a 2-arene-azaindole-based tracer...